Amyloid ß-peptide (Aß), Aß precursor protein (APP), apolipoprotein E (apoE), and elevated cholesterol levels have been linked to Alzheimer's disease (AD) pathology. High cholesterol levels increase APP and apoE expression in human NT2 neuron progenitor cells. A cholesterolrich environment also induces processing of APP, leading to the formation of Aß and Aß peptide fragments. Using a novel method, we determined that 1) cholesterol binds to Aß at α-secretase cleavage site; 2) Aß 17-40 rather than Aß 1-40 prevents cholesterol from binding to apoE; 3) Aß 1-40 inhibits cholesterol from binding to low-density lipoprotein (LDL), leading to decrease cholesterol influx and intracellular cholesterol levels; 4) the binding of cholesterol to apoE or LDL was abolished completely in presence of Aß . Increased extracellular free cholesterol levels are toxic to neurons; this toxicity is prevented by specific lipoproteins, such as highdensity lipoproteins, which maintain their ability to bind cholesterol in the presence of Aß. We propose that one of the physiological functions of Aß and APP is to control cholesterol transport. AD is associated with increased Aß production. High cholesterol levels also lead to overproduction of Aß. Aß blocks cholesterol trafficking and changes cholesterol homeostasis leading to neurodegeneration and the onset and/or progression of AD pathology.
A growing body of evidence suggests that high cholesterol levels might be linked to AD. ApoE4 has been associated with high cholesterol levels (4), and hypercholesterolemia is considered a risk factor associated with AD (5) . Epidemiological studies indicate that the prevalence of AD is reduced among people treated with inhibitors of cholesterol biosynthesis, that is, statins (6, 7) , and animal studies support these results (8, 9) . In search of the mechanism of action of cholesterol that might be leading to AD pathology, numerous in vitro and in vivo studies have shown that cholesterol modulates APP processing and affects APP mRNA expression (10) (11) (12) (13) . Moreover, it has been shown that Aß binds to apoE, a lipid and cholesterol transport protein responsible for the efflux of cholesterol from neurons (14) to form stable complexes both in vitro and in vivo (15) (16) (17) . In addition, using fluorescent-labeled cholesterol and lipids, binding of cholesterol and phosphatidylcholine to APP and Aß has also been demonstrated (18, 19) . These data that indicate a link between cholesterol, APP, apoE, and AD lead us to hypothesize that one of the physiological functions of APP might be to control cholesterol movement across neuronal membranes. We therefore considered that APP and Aß might act as regulatory proteins to modulate cellular cholesterol levels. We determined APP and apoE mRNA expression and protein production in human NT2 neuron precursor cells exposed to cholesterol. To detect the cholesterol-Aß and cholesterol-apoE/lipoprotein binding under native conditions, we established a novel method, the cholesterol-protein binding blot assay (CPBBA). Using this method the direct binding, under native conditions, of cholesterol to Aß and the effect of Aß on the interaction between cholesterol and apoE or other lipoproteins were examined. Finally, we investigated the role of cholesterol in the mechanisms underlying Aß-induced neurotoxicity.
MATERIALS AND METHODS

Materials, cell culture, and cellular toxicity assay
The source of materials used in this study were as follows: apoE (E2, E3 and E4) were from Calbiochem; human apoE was from Chemicon; human LDL and HDL were from Sigma (St. Louis, MO); goat anti-apoE polyclonal antibody and rabbit anti-amyloid precursor polyclonal antibody were from Chemicon (cat. no. AB5300; Temecula, CA); rabbit anti-amyloid precursor protein-ß for CTFα detection (cat. no. 51-2700) and polyclonal rabbit anti-ß-amyloid peptide (cat.no. 71-5800) were from Zymed Laboratories (San Francisco, CA); [1,2-3 H(N)]-cholesterol (sp. act. 48.3 Ci/mmol; NEN Life Science Products, Inc., Boston, MA); Aß and Aß fragments were from American Peptide Company (Sunnyvale, CA), dissolved in distilled water or 50 mM Tris-HCl (pH 7.5) buffer following the instructions of the supplier and kept at 4-8°C for 2 weeks. Formed Aß aggregates were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (20) . NT2 precursor cells (Ntera2/D1) were obtained from Stratagene (La Jolla, CA) and cultured following the instructions of the supplier. The cellular toxicity assay for Aß and Aß fragments was performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sheffield, UK) assay (Trevigen, Gaithersburg, MD) as previously described (20) .
Immunoblot analysis and RT-PCR
After the indicated treatments, cells were washed three times with phosphate buffered saline (PBS). Proteins were separated by SDS-PAGE on 4-20% gradient acrylamide/bis-acrylamide gel (Invitrogen) at 125 V for 2 h and transferred onto 0.45 µm nitrocellulose membrane (Schleicher & Schuell, Keene, NH) Nonspecific absorption of antibodies was blocked by incubating the nitrocellulose in 5% milk. Blots were treated for immunodetection of Aß, APP, CTFα, and apoE and were visualized by using ECL reagents (Amersham Pharmacia Biotech, Uppsala, Sweden) (21) . Antibodies were used at the following concentrations or dilutions: anti-Aß at 0.2 µg/ml, anti-APP at 1:1000, anti-CTFα at 0.2 µg/ml and anti-apoE at 1:2500. Secondary antibody was used at 1:5000 dilution. Total RNA from NT2 cells was isolated by using the RNAzol B reagent (Tel-Test Inc., Friendswood, Texas). Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed by using a GeneAmp RNA-PCR Core Kit (Applied Biosystems, Foster City, CA). The following primers were used: for APP, 5'--ATG CTG CCC GGT TTG GCA CTG CTC--3' (forward) and 5'--GGT ACT GGC TGC TGT TGT AGG AAG--3' (reverse) generating a product of 1100 bp; for apoE, 5'-GCG CGG ATG GAG GAG ATG GGC AGC--3' (forward) and 5'-TCA GTG ATT GTC GCT GGG CAC AGG--3' (reverse) generating a fragment of 270 bp; and for GAPDH, 5'--CCA TGG AGA AGG CTG GGG C--3' (forward) and 5'--CCA AAG TTG TCA TGG ATG--3' (reverse) generating a product of 500 bp. The identity of the generated PCR products was confirmed by automatic sequencing performed by using the ABI Prism Dye Terminator Cycle Sequencing ready reaction kit (Perkin Elmer, Foster City, CA). DNA sequencing was performed at the Lombardi Cancer Center Sequencing Core Facility (Georgetown University Medical Center). Image-densitometric analysis of the immunoreactive protein bands and RT-PCR DNA bands was performed by using the OptiQuant-image analysis software (Packard BioScience, Foster City, CA).
Cholesterol-protein binding blot assay (CPBBA)
Purified Aß protein (50 µM) or various Aß fragments (50 µM) and 3 H-cholesterol (0.15 µCi) were incubated either alone or in the presence of increasing concentrations of unlabeled cholesterol in 20 µl PBS final volume for 24 h at 37°C. In other experiments, 2 µg of isolated lipoproteins, apoE or 0.5 U cholesterol esterase were incubated with 3 H-cholesterol (0.1µCi for apoE and cholesterol esterase, 0.02µCi for lipoproteins) in the presence or absence of increasing concentrations of Aß or various Aß fragments in 20 µl volume at 37°C for 1 h (apoE and cholesterol esterase) or 3 h (lipoproteins). Optimal incubation times and cholesterol concentrations were determined in preliminary experiments. At the end of the incubation time, the samples were separated by 1.5% agarose (Type I-B, Sigma) gel electrophoresis and transferred to nitrocellulose membrane in 10× SSC buffer. The membrane was exposed to tritium-sensitive screen and analyzed by phosphoimaging using the Cyclone Storage phosphor system (Packard BioScience). Image-densitometric analysis of the radioactivity was performed as described above. This method allowed for the separation, visualization, and identification of high-molecular-weight Aß complexes ( Fig. 2 ) and isolated lipoproteins, apoE and cholesterol esterase (Figs. 3, 4 and 5), which have incorporated radiolabeled cholesterol under native conditions. Low molecular weight unincorporated cholesterol is separated and eliminated during electrophoresis.
H-Cholesterol uptake assay
NT2 cells (2 × 10 5 ) were incubated in presence of 0.15 µCi 3 H-cholesterol for 24 h in the presence or absence of the indicated concentration of Aß fragments. At the end of the incubation time, cells were washed with PBS and lysed in 0.2 ml of 0.1 N NaOH. Radioactivity was measured by liquid scintillation spectrometry. Protein levels were quantified by the dye-binding assay of Bradford (22) by using bovine serum albumin as standard.
RESULTS
Cholesterol increases APP/apoE levels and affects APP processing
NT2 cells were treated with cholesterol for 12 ( Fig. 1a, b ) or 72 h (Fig. 1c, d ). APP protein and mRNA levels were determined by immunoblot and RT-PCR analyses. Exposure of the cells to cholesterol for 12 h did not affect APP protein level. However, APP mRNA levels increased in the presence of increasing concentrations of cholesterol by 25% at 1 µM to 50% at 100 µM cholesterol. Exposure of the cells to increasing concentrations of cholesterol for 72 h resulted in a dose-dependent increase of both APP protein and mRNA levels ranging from 25% at 1 µM to 75% at 100 µM cholesterol. Cholesterol also affected, in a dose-dependent manner, NT2 apoE protein and mRNA levels; 12-and 72-h exposure to high concentrations of cholesterol induced apoE protein (Fig. 1e, g ). Cholesterol also increased apoE mRNA levels after 12 h treatment (Fig. 1f ), but had no significant effect on apoE mRNA expression after 72 h treatment (Fig. 1h) . To evaluate the influence of cholesterol on APP processing, the levels of C-terminal fragment (CTF α ) of APP, a 10 kDa peptide produced by α-secretase cleavage, were determined in the same blots by using specific anti-CTF α antisera. NT2 CTF α levels were decreased in response to a 12-h exposure to high cholesterol concentrations by 25% at 1 µM to 60% at 100 µM, compared to control (Fig. 1a) . This was probably due to decreased APP processing by α-secretase. However, CTF α levels were increased by cholesterol, in a dose-dependent manner, after 72 h treatment of the cells (Fig. 1c) . This increase over time suggests that after an initial lag period APP processing is induced by cholesterol. In conclusion, the results presented in Figure 1 suggest that, in the presence of high cholesterol levels, there is increased APP and apoE synthesis and increased APP processing to Aß and Aß peptide fragments.
Cholesterol binds to Aß at the α-secretase cleavage site
CPBBA was used to study the direct interaction between Aß and cholesterol. The generated pattern shows that after 24 h incubation at 37°C the intensity of radiolabeling of Aß with 3 Hlabeled cholesterol decreased in the presence of increasing concentrations of unlabeled cholesterol (Fig. 2a) . Cholesterol did no bind to Aß when the reaction occurred at 4°C, suggesting that the temperature-sensitive state of Aß is critical for the interaction with cholesterol. The radiolabeled bands were identified as Aß by using an antibody specific to Aß (Fig. 2b) ; note that despite the decreased radiolabeling of Aß there are no differences in the amount of Aß present in each lane. These data demonstrate that under native conditions cholesterol binds to Aß. By use of CPBBA, the cholesterol-binding site in Aß was mapped and found to be in amino acids 10-20 of Aß (Fig. 2c) . The site where α-secretase acts to cleave APP is within the cholesterol-binding site (10; Fig. 2d ). These data indicates that in the presence of low cholesterol levels APP will be cleaved by α-secretase generating the Aß 17-40 peptide. However, in the presence of high cholesterol levels, cholesterol binds to the α-secretase cleavage site of APP thus blocking the action of the enzyme leading to the generation of Aß 1-40 rather than Aß .
Aß affects cholesterol-apoE/LDL binding. The high-density (HDL) and low-density (LDL) lipoproteins are the main carriers of cholesterol that mediate its transport between peripheral tissues and liver and cholesterol influx into cells (23) (24) (25) . In contrast, apoE is a cholesterol transport protein and mediates cholesterol efflux from cells (26) (27) (28) . The effect of Aß , Aß and Aß 1-42 on free cholesterol uptake/influx by NT2 cells was evaluated (Fig. 3a) . In contrast to its effect on the apoE-mediated cholesterol efflux mechanism, Aß 17-40 did not affect cholesterol uptake by the cells. However, addition of Aß 1-40 and Aß 1-42 decreased cholesterol uptake. Using CPBBA, we examined the possibility that Aß and the generated Aß peptides affect the binding of cholesterol to either apoE or lipoprotein. The results obtained show that the C-terminal fragment of Aß, Aß , prevents cholesterol from binding to apoE (Fig. 3b) ; the binding of cholesterol to apoE was almost abolished in presence of Aß [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Fig. 3c) . As for Aß , the interaction between cholesterol and apoE or LDL was completely abolished, suggesting an effect of this peptide on the amount of cholesterol transported during both cholesterol efflux and influx. There was no effect of Aß on the HDL-cholesterol binding (Fig. 3d) .
In short incubation time period (2 h), and in the absence of apoE, only low binding of cholesterol to Aß and Aß 17-40 can be seen (Fig. 4a) . The effect of Aß 17-40 on cholesterol binding to apoE (100 µg protein /ml) was dose-dependent with an IC 50 of 25 µM (Fig. 4b) . The IC 50 of the effect of Aß 1-40 on cholesterol binding to LDL (100 µg protein/ml) was 10 µM (Fig. 4c) . IC 50 values for Aß and Aß 1-40 depend on the amount of apoE and lipoprotein present in the reaction mixture; decreasing the concentration of apoE and lipoprotein results in lower IC 50 values. Aß 17-40 also inhibited in a concentration-dependent manner, the binding of cholesterol to three common isoforms of apoE, apoE2 (Fig. 4d), apoE3 (Fig. 4e), and apoE4 (Fig. 4f) . In all cases, significant inhibitions were observed with 25µM Aß . Aß , even at high concentrations, did not affect the binding of cholesterol to apoE2, apoE3, and apoE4. These data suggest that in a low cholesterol environment, where there is more of the Aß 17-40 peptide, the amount of cholesterol exported by apoE from the cell (cholesterol efflux) decreases, leading to increased intracellular cholesterol levels. In the presence of high cholesterol levels, the elevated Aß 1-40 formation does not affect the apoE-mediated cholesterol efflux. In agreement with the cholesterol uptake data, Aß , even at high concentrations, does not affect cholesterol binding to LDL. These data also suggest that in a high cholesterol environment the generated Aß decreases the amount of cholesterol transported by LDL into the cells (cholesterol influx), leading to decreased cellular cholesterol levels. Figure 5a shows that the Aß and Aß peptide fragments are toxic to NT2 human neurons, as determined using the MTT assay. Because NT2 cells are maintained in media supplemented with fetal bovine serum that contains the cholesterol-binding proteins cholesterol esterase and bovine lipoprotein, we examined the ability of Aß and Aß peptide fragments to block cholesterol binding to these proteins. Figure 5b shows that Aß 1-42 , Aß 25-35, but not Aß 35-25 and, to a lesser extent, Aß , inhibited cholesterol binding to cholesterol esterase as determined by CPBBA. This will result in increased levels of free cholesterol in the media. Because the same peptides were found to be toxic to the cells (Fig. 5a) , we propose that this newly released free cholesterol might be mediating the Aß toxicity. Indeed, free cholesterol decreased neuronal cell viability in a dose-dependent manner (Fig. 5c) . Considering that bovine lipoprotein binds cholesterol and Aß and Aß peptide fragments cannot efficiently compete this interaction (Fig. 5d) , we tested the ability of bovine lipoprotein to bind free cholesterol, released by other cholesterol proteins in the presence of Aß or Aß peptide fragments. Figure 5e shows that bovine lipoprotein protects against the Aß-induced neurotoxicity. Similar results were obtained by using human HDL (data not shown), another lipoprotein that Aß and Aß peptide fragments cannot compete against for its interaction with cholesterol (Fig. 3d) . These results suggest that a high-cholesterol environment leads to neurotoxicity that can be prevented by using lipoproteins, which interact with cholesterol in a manner resistant to Aß and Aß peptide fragments.
Cholesterol induces and lipoprotein prevents Aß-induced neurotoxicity
DISCUSSION
Despite the large number of studies on the role of APP, apoE, and high cholesterol levels in AD, the detailed molecular mechanisms underlying the actions of these entities leading to the onset and/or progression of the disease have not yet been elucidated. Mutations of APP and PS genes lead to accumulation of Aß and have been described as the leading cause of familial AD. Highcholesterol levels also lead to overproduction of Aß and may be responsible for the development of sporadic AD. Elevated cholesterol levels might also accentuate the onset and progression of AD, due to either APP or PS mutations or other yet unknown factors, leading to either sporadic or familial AD. The possibility that Aß-induced alterations in cellular cholesterol metabolism could contribute to neurodegeneration has been brought up (26) , and the abnormal lipid composition of cellular membranes in AD brain has been reported (23, 24) . Considering that growth and maintenance of an elaborate neurite network requires directional lipid transport (25) , alterations in lipid transport might be detrimental to neuronal integrity. In addition to these data, it has been established now that apoE, a major risk factor in AD, is a component of lipoproteins responsible for the efflux of cholesterol from neurons (27) ; apoE2 been more efficacious than apoE3 and apoE4 to mediate cholesterol efflux (28) . Moreover, it has been shown that Aß binds to apoE (15) (16) (17) 29) . Taken together these results indicate changes in cholesterol transport, and thus homeostasis, as a lead to Aß-mediated neurotoxicity. To examine the role of cholesterol homeostasis in neurodegeneration, we investigated changes induced by low and high cholesterol concentrations on APP, Aß, and apoE levels, and we developed a novel method to examine the role of Aß and Aß peptide fragments on apoE and LDL-mediated cholesterol transport, with LDL responsible for cholesterol transfer into the cells (30) (31) (32) .
In the present study, evidence is provided that in the presence of low cholesterol levels and in an environment where Aß exists either normally or induced by APP or PS mutations, APP will be cleaved by α-secretase generating the Aß 17-40 peptide in addition to Aß . Because there is more of the Aß 17-40 peptide, the amount of cholesterol exported by apoE from the cells decreased, leading to increasing intracellular cholesterol levels.
In the presence of high cholesterol levels, there is increased APP synthesis and processing to Aß and Aß peptide fragments, which agrees with previous reports (11 -13) . Moreover, there is increased apoE synthesis leading to increased cholesterol efflux. Cholesterol binds to the α-secretase cleavage site of APP and blocks the action of the enzyme, which results in the generation of Aß 1-40 rather than Aß . Aß 1-40 does affect neither the apoE-mediated cholesterol efflux, which is elevated because of increased apoE levels, nor the binding of cholesterol to apoE. However, it blocks the amount of cholesterol bound and transported by LDL into the cells, leading to decreased intracellular cholesterol levels. Accumulation of extracellular or membrane free cholesterol will result in neuronal dysfunction. Thus, the presence of excessive levels of cholesterol lead to increased production of Aß, which binds cholesterol and in turn competes against and blocks the LDL-mediated cholesterol influx. Accumulation of extracellular free cholesterol and the subsequent neurotoxicity can be prevented by addition of specific lipoproteins that bind cholesterol in a manner resistant to Aß and Aß peptide fragments. HDL is one of these lipoproteins that also binds cholesterol with higher affinity than apoE (not shown), thus taking cholesterol back to the liver. Aß does not affect cholesterol binding to HDL, which suggests that Aß does not affect the process of cholesterol elimination. A schematic representation of the cholesterol-induced changes in APP processing and the Aß-induced changes in cholesterol transport is shown in Figure 6 .
In conclusion, we propose that one of the physiological functions of Aß and APP is to control cholesterol transport and homeostasis. Overproduction of Aß, due to either mutation of APP and PS genes or high cholesterol levels, blocks cholesterol trafficking, leading to neurodegeneration and the development of familial or sporadic AD pathology. 6 . Cholesterol-induced mechanism leading to AD pathology. The proposed scheme suggests that cholesterolinduced changes in Aß levels and processing alters lipoprotein-and apoE-mediated cholesterol transport leading to neurotoxicity and AD pathogenesis.
